Therapeutic monoclonal antibody targeting the TLR2 receptor for treatment of myelodysplastic syndrome (MDS), currently in Phase II with an orphan-drug filing. Aims to treat MDS patients with cytopenias (thrombocytopenia, neutropenia, anemia) to reduce progression risk to acute myeloid leukemia.